Pfizer and Lilly shoulder novel pain-drug risks

Sinha, Gunjan
January 2014
Nature Biotechnology;Jan2014, Vol. 32 Issue 1, p9
Academic Journal
The article reports on the deal between pharmaceutical companies New York-based Pfizer and Eli Lilly & Co. in Indianapolis, Indiana in October 2013 for the development of the former's anti-nerve growth factor drug known as tanezumab.


Related Articles

  • Learning from the Drug Companies. Jackson, David A. // American Chiropractor;Mar2005, Vol. 27 Issue 3, p30 

    The article reports that in 2003, members of the pharmaceutical industry's trade organization the Pharmaceutical Research and Manufacturers of America spent an estimated $33.2 billion on research to develop new drugs. As of 2000, Eli Lilly & Co., for instance, reinvested nearly 20% of its...

  • Look Beyond Biopharmoceulical Industry Hype. Miller, Jim // BioPharm International;Jan2008, Vol. 21 Issue 1, p22 

    The article focuses on the speculation for market rejection of Exubera from Pfizer Inc., and for development of Technosphere insulin from Mannkind Corp. as well as the prospects for the inhaled insulin product developed by Eli Lilly & Co. and Alkermes Inc. in the U.S. According to the author,...

  • Eli Lilly and Company SWOT Analysis.  // Eli Lilly&Company SWOT Analysis;Mar2014, p1 

    The article presents a strengths, weaknesses, opportunities and threats (SWOT) analysis of the global pharmaceutical company Eli Lilly and Co. in 2014. Topics discussed include the company's leadership position in the international diabetes market, the impact of patent expiry on corporate...

  • ICAD 2009: beta-amyloid remains center stage at Alzheimer's disease conference.  // PharmaWatch: Monthly Review;Sep2009, Vol. 8 Issue 9, p18 

    The article recapitulates the topics presented at the International Conference on Alzheimer's Disease (ICAD) 2009. These include the metal protein being developed by Prana Biotechnology Ltd. to attenuate the compound PBT2. Dr. Siemers of Ely Lilly & Co. provides the overview of the clinical...

  • An analysis of the attrition of drug candidates from four major pharmaceutical companies. Waring, Michael J.; Arrowsmith, John; Leach, Andrew R.; Leeson, Paul D.; Mandrell, Sam; Owen, Robert M.; Pairaudeau, Garry; Pennie, William D.; Pickett, Stephen D.; Wang, Jibo; Wallace, Owen; Weir, Alex // Nature Reviews Drug Discovery;Jul2015, Vol. 14 Issue 7, p475 

    The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development. Attempts to reduce the number of efficacy- and safety-related failures by analysing possible links to the physicochemical properties of small-molecule drug candidates have been...

  • Drug firms join forces to boost discovery pipeline.  // Nature;7/17/2008, Vol. 454 Issue 7202, p265 

    This article discusses a partnership between Merck & Co. inc., Pfizer Inc., and Eli Lilly & Co. to form the start-up company Enlight Biosciences. This company will develop laboratory technologies at the pre-competitive stage, passing on proprietary technology for the drug development process....

  • 2013 PIPELINE REPORT. Comer, Ben; Looney, William // Drug Topics;Feb2013, Vol. 157 Issue 2, p40 

    The article presents information on research and development (R&D) being conducted on drugs in the U.S. Pfizer and Johnson & Johnson have ended their joint development program on bapineuzumab, a monoclonal antibody targeting beta amyloid in the brains of Alzheimer's patients. Eli Lilly & Co. has...

  • Pharma: Clinic Roundup.  // BioWorld Today;5/13/2013, Vol. 24 Issue 91, p9 

    The article reports that Eli Lilly and Co. of Indianapolis, Indiana will stop development of enzastaurin, a monotherapy in preventing relapse in patients with diffuse large B-cell lymphoma, based on findings of Phase III PRELUDE study of enzastaurin.

  • Pharmaceutical futures: Made in China? Cyranoski, David // Nature;10/30/2008, Vol. 455 Issue 7217, p1168 

    The article discusses the pharmaceutical industry in China. It states that the Chinese government is serious on meeting international standards for drug development with $900 million investment. The investment aimed at good practices in laboratory and clinical practice. Multinational companies...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics